Anixa Biosciences (NASDAQ:ANIX) Stock Bumped Down to “Sell” by Wall Street Zen

Wall Street Zen downgraded shares of Anixa Biosciences (NASDAQ:ANIX) from a hold rating to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

ANIX has been the topic of several other reports. HC Wainwright dropped their target price on Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, September 22nd. Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a report on Tuesday, October 6th. Weiss Ratings upgraded Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. Finally, Zacks Research cut shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Anixa Biosciences currently has a consensus rating of “Hold” and a consensus price target of $8.00.

Anixa Biosciences Price Performance

NASDAQ ANIX opened at $3.12 on Friday. Anixa Biosciences has a 1 year low of $2.32 and a 1 year high of $5.46. The company has a market capitalization of $108.45 million, a PE ratio of -9.75 and a beta of 0.47. The company has a fifty day moving average of $2.97 and a 200 day moving average of $2.97.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). Research analysts expect that Anixa Biosciences will post -0.31 earnings per share for the current year.

Insider Buying and Selling at Anixa Biosciences

In other news, Director Lewis Titterton, Jr. bought 49,036 shares of the stock in a transaction dated Wednesday, September 23rd. The shares were acquired at an average cost of $2.69 per share, with a total value of $131,906.84. Following the purchase, the director directly owned 1,046,003 shares in the company, valued at $2,813,748.07. The trade was a 4.92% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have bought a total of 100,536 shares of company stock valued at $275,737 in the last three months. Corporate insiders own 26.40% of the company’s stock.

Hedge Funds Weigh In On Anixa Biosciences

Several institutional investors and hedge funds have recently modified their holdings of ANIX. BlackRock Inc. purchased a new stake in shares of Anixa Biosciences in the second quarter valued at approximately $559,000. AXQ Capital LP acquired a new position in shares of Anixa Biosciences during the 2nd quarter worth approximately $41,000. Corient Private Wealth LP acquired a new position in shares of Anixa Biosciences during the 2nd quarter worth approximately $105,000. Canada Pension Plan Investment Board acquired a new position in shares of Anixa Biosciences during the 2nd quarter worth approximately $38,000. Finally, Sanctuary Advisors LLC purchased a new position in shares of Anixa Biosciences during the 2nd quarter valued at approximately $29,000. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. The company’s programs are designed to use the immune system to identify and attack disease-associated targets.

Anixa’s oncology pipeline has included a chimeric antigen receptor T-cell (CAR-T) therapy targeting the follicle-stimulating hormone receptor, which is being investigated as a potential treatment for ovarian cancer and other cancers.